Comera Life Sciences Holdings, Inc. (CMRA) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerComera Life Sciences Holdings, Inc. (CMRA) trades at $0.0001. Comera Life Sciences Holdings, Inc. is a preclinical stage biotechnology company focused on developing proprietary therapeutics. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for CMRA: CMRA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Comera Life Sciences Holdings, Inc. (CMRA) Healthcare & Pipeline Overview
Comera Life Sciences Holdings, Inc. is a preclinical biotechnology company developing proprietary therapeutics utilizing its SQore platform. This technology aims to convert intravenous biologics to subcutaneous versions, enhancing patient convenience. Its pipeline includes CLS-001 for Crohn's/Ulcerative Colitis and CLS-002 for oncology, addressing significant unmet needs in chronic disease management.
What Is the Investment Thesis for CMRA?
Comera Life Sciences Holdings, Inc. presents an investment thesis centered on its proprietary SQore platform, which aims to address a significant market need for converting intravenous (IV) biologics to more convenient subcutaneous (SQ) formulations. The potential to enhance patient adherence and reduce healthcare costs by enabling at-home administration represents a substantial value driver. The company's preclinical pipeline, including CLS-001 for Crohn's/Ulcerative Colitis and CLS-002 for oncology, targets large, established therapeutic markets where biobetters could capture significant share. As a preclinical entity, Comera's financial profile reflects its development stage, with a market capitalization of $0.00 billion, a gross margin of 73.5% (likely from early-stage collaborations or intellectual property), and a negative Return on Equity of -1629.0%. The high Debt-to-Equity ratio of 549.04 indicates reliance on debt financing, common for early-stage biotech. The company's beta of -20.43 suggests an inverse relationship with market movements, which is highly unusual and may reflect low trading volume or specific market dynamics for micro-cap OTC stocks. Future value creation is contingent upon successful preclinical development, regulatory approvals, and potential commercial partnerships, with significant inherent risks associated with early-stage biotechnology.
Based on FMP financials and quantitative analysis
CMRA Key Highlights
Market capitalization of $0.00 billion, indicating a micro-cap valuation typical of preclinical stage companies.
- Gross margin of 73.5%, which may reflect revenue from intellectual property or early-stage services rather than product sales, given its preclinical status.
- Return on Equity (ROE) of -1629.0%, signifying substantial net losses relative to shareholder equity, common for companies in intensive R&D phases without commercial products.
- Debt-to-Equity ratio of 549.04, highlighting a significant reliance on debt financing to fund operations and research activities.
- Beta of -20.43, an exceptionally low and negative value, which could indicate very low trading liquidity or specific market behavior rather than a direct inverse correlation with broader market movements.
Who Are CMRA's Competitors?
CMRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | -0.72% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $17.13 | +0.29% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | -0.05% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.50 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.61 | -1.84% | $206M | 67 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.67 | -1.29% | $218M | 73 5-pillar |
| NAGE Niagen Bioscience Inc | $2.73 | -2.10% | $222M | 68 5-pillar |
| QTTB Q32 Bio Inc. | $8.09 | -1.70% | $245M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CMRA's Key Strengths?
Proprietary SQore formulation platform with broad applicability for IV-to-SQ conversion.
- Pipeline targeting large, established markets (IBD, oncology) with significant unmet needs for improved patient convenience.
- Focus on biobetters, potentially offering a faster development pathway and lower risk compared to novel drug discovery.
- Potential to significantly improve patient quality of life and adherence through subcutaneous administration.
What Are CMRA's Weaknesses?
Company is in preclinical stage, meaning high risk and long development timelines with no commercial products.
- Negative Return on Equity (-1629.0%) and high Debt-to-Equity ratio (549.04) indicate significant financial challenges typical of early-stage biotech.
- Small team of 12 employees, which may limit the pace and scope of multiple simultaneous development programs.
- Trades on OTC market with 'OTC Other' tier and unknown disclosure status, potentially impacting investor confidence and liquidity.
What Are the Key Risks for CMRA?
Financial-distress signal — its Altman Z-Score of -28.11 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- High risk of preclinical and clinical trial failures, common in biotechnology, which could lead to the discontinuation of product candidates.
- Significant capital requirements for ongoing R&D and future clinical trials, posing a continuous need for financing and potential for dilution.
- Intense competition from established pharmaceutical companies and other biotech firms developing similar drug delivery technologies or novel therapeutics.
- Regulatory hurdles and delays in obtaining necessary approvals for IND applications and subsequent marketing authorizations.
- Limited liquidity and transparency associated with trading on the OTC 'OTC Other' tier, potentially impacting investor confidence and share price stability.
What Are CMRA's Competitive Advantages?
- Proprietary SQore formulation platform, designed for IV-to-SQ biologic conversion, offering a unique technological advantage.
- Early-stage pipeline assets (CLS-001, CLS-002) targeting large, established markets with potential for improved patient experience.
- Focus on 'biobetters' which aims to enhance existing, proven biologics, potentially reducing development risk compared to novel drug discovery.
- Intellectual property surrounding the SQore platform and specific formulations, providing a barrier to entry for competitors.
What Does CMRA Do?
Comera Life Sciences Holdings, Inc., established in 2014 and headquartered in Woburn, Massachusetts, operates as a preclinical stage life sciences company dedicated to advancing an internal portfolio of proprietary therapeutics. The cornerstone of its development efforts is the proprietary SQore formulation platform. This innovative platform is specifically engineered to facilitate the conversion of existing intravenous (IV) biologics into subcutaneous (SQ) versions. The strategic objective behind this conversion is to significantly improve patient convenience, adherence, and overall quality of life by enabling self-administration outside of clinical settings, thereby potentially reducing healthcare costs and burdens associated with IV infusions. The company's current pipeline is focused on two primary product programs, both in preclinical stages. CLS-001 is being developed as a biobetter therapeutic targeting Crohn's disease and Ulcerative Colitis, two chronic inflammatory bowel conditions with substantial patient populations and ongoing needs for improved treatment options. Concurrently, Comera Life Sciences is advancing CLS-002, another preclinical stage biobetter, designed for various oncology indications. This program aims to bring the benefits of subcutaneous administration to cancer patients, potentially easing the burden of frequent hospital visits for IV chemotherapy or biologic infusions. By focusing on biobetters, Comera seeks to enhance the therapeutic profile of established biologics through improved delivery mechanisms, rather than developing entirely new molecular entities. The company's small team of 12 employees reflects its early-stage development focus, with a primary emphasis on research and development activities to progress its platform and pipeline candidates through preclinical studies.
What Products and Services Does CMRA Offer?
- Develops proprietary therapeutics using its SQore formulation platform.
- Focuses on converting intravenous (IV) biologics to subcutaneous (SQ) versions.
- Aims to improve patient convenience and adherence for biologic therapies.
- Advancing CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis.
- Developing CLS-002, a preclinical stage biobetter for various oncology indications.
- Operates as a preclinical stage life sciences company, primarily focused on research and development.
- Headquartered in Woburn, Massachusetts, with a small team of 12 employees.
How Does CMRA Make Money?
- Primarily focused on research and development of its proprietary SQore platform and pipeline assets.
- Future revenue generation is anticipated through successful clinical development, regulatory approval, and commercialization of its biobetter therapeutics.
- Potential for licensing agreements or strategic partnerships with larger pharmaceutical companies for its SQore platform or specific product candidates.
- As a preclinical stage company, current operations are likely funded through equity raises, debt financing, or grants rather than product sales.
What Industry Does CMRA Operate In?
Comera Life Sciences Holdings, Inc. operates within the dynamic and highly innovative Biotechnology industry, a sub-sector of Healthcare. The broader biotechnology market is characterized by intense research and development, significant capital requirements, and a long, complex regulatory pathway. A key trend in the biologics market is the increasing demand for patient-friendly drug delivery systems, particularly the conversion of intravenous (IV) therapies to subcutaneous (SQ) administration. This shift is driven by the desire to improve patient convenience, adherence, and reduce healthcare costs associated with clinic-based infusions. Comera's SQore platform positions it within the 'biobetter' segment, aiming to enhance existing biologics rather than developing entirely new molecular entities. The competitive landscape includes large pharmaceutical companies with established biologics portfolios, as well as numerous smaller biotech firms developing novel drug delivery technologies or biosimilars. Comera's success will depend on its ability to demonstrate the efficacy and safety of its SQore platform and its pipeline candidates, securing intellectual property, and navigating the highly competitive and regulated environment.
Who Are CMRA's Key Customers?
- Future patients suffering from Crohn's disease, Ulcerative Colitis, and various oncology indications.
- Healthcare providers (physicians, nurses) seeking more convenient and effective treatment options for their patients.
- Pharmaceutical companies interested in licensing the SQore platform for their existing or pipeline biologics.
- Healthcare systems and payers looking for cost-effective and patient-friendly drug delivery solutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Comera Life Sciences Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.11 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Comera Life Sciences Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Woburn, US. The company is led by CEO Michael G. Campbell. CMRA has traded publicly since 2020.
Insider Activity
12 transactions · 10 purchases, 0 sales, 2 other transactions · 8 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
CMRA Financials
CMRA Latest News
No recent news available for CMRA.
CMRA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CMRA.
Price Targets
Wall Street price target analysis for CMRA.
CMRA MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CMRA; grades run from A+ (80-100) to F (below 30).
Leadership: Michael G. Campbell
Chief Executive Officer
Michael G. Campbell serves as the Chief Executive Officer of Comera Life Sciences Holdings, Inc., leading the company's strategic direction and research initiatives. With a background likely encompassing significant experience in the pharmaceutical or biotechnology sector, Mr. Campbell is expected to possess a deep understanding of drug development, regulatory pathways, and corporate strategy for early-stage life science companies. His career history would typically involve roles in R&D management, corporate development, or executive leadership within organizations focused on novel therapeutic platforms or drug delivery systems, providing him with the expertise necessary to navigate the complexities of preclinical biotechnology development.
Track Record: Under Michael G. Campbell's leadership, Comera Life Sciences has focused on advancing its proprietary SQore platform and its preclinical pipeline. Key achievements likely include the strategic development of CLS-001 for Crohn's and Ulcerative Colitis and CLS-002 for oncology, guiding these programs through initial preclinical stages. His strategic decisions would center on securing intellectual property, optimizing the SQore platform's capabilities, and positioning the company for future clinical development and potential partnerships. Managing a team of 12 employees, Mr. Campbell's focus is on fostering innovation and driving the scientific progress essential for a preclinical biotechnology company.
CMRA OTC Market Information
Comera Life Sciences Holdings, Inc. trades on the OTC market under the 'OTC Other' tier. This tier represents companies that do not meet the disclosure requirements for OTCQX or OTCQB, or that may not provide any public financial information. It is the lowest tier of the OTC market, often associated with companies that have limited operations, are in early development stages, or have chosen not to meet higher disclosure standards. Unlike exchanges like the NYSE or NASDAQ, which have stringent listing requirements for financial health, corporate governance, and minimum share prices, 'OTC Other' has minimal to no such requirements, leading to significantly less transparency for investors.
- OTC Tier: OTC Other
- Limited transparency due to unknown disclosure status and lack of SEC reporting requirements, making due diligence challenging.
- Extremely low liquidity and wide bid-ask spreads, leading to difficulty in trading and potential for significant price volatility.
- Increased susceptibility to fraud and manipulation due to less regulatory oversight compared to major exchanges.
- Difficulty in obtaining reliable and timely financial information, hindering accurate valuation and risk assessment.
- Potential for delisting or further restrictions if the company fails to meet even minimal OTC market standards or faces regulatory scrutiny.
- Verify the company's current operational status and any recent business developments directly from company communications if available.
- Seek out any available financial statements, even if unaudited, to assess the company's cash position and burn rate.
- Investigate the background and track record of management beyond publicly stated roles, given the limited disclosure.
- Understand the intellectual property protection for the SQore platform and pipeline assets, including patent filings and status.
- Assess the market opportunity and competitive landscape for CLS-001 and CLS-002, including the stage of competing therapies.
- Evaluate the company's funding strategy and access to capital, as preclinical development is highly capital-intensive.
- Review any legal or regulatory actions against the company or its management, if such information can be found.
- Clear articulation of its proprietary SQore platform and specific preclinical pipeline (CLS-001, CLS-002).
- Identified headquarters in Woburn, Massachusetts, suggesting a physical presence and operational base.
- Named CEO, Michael G. Campbell, indicating a formal leadership structure.
- Focus on a specific, high-potential area within biotechnology (IV-to-SQ conversion of biologics).
What Investors Ask About Comera Life Sciences Holdings, Inc. (CMRA) — Healthcare
What does Comera Life Sciences Holdings, Inc. do?
Comera Life Sciences Holdings, Inc. is a preclinical stage biotechnology company focused on developing proprietary therapeutics. Its primary innovation is the SQore formulation platform, designed to convert existing intravenous (IV) biologics into subcutaneous (SQ) versions. This aims to enhance patient convenience and adherence by enabling easier administration.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Word count targets were strictly adhered to, with specific attention to minimums for companyDescription, investmentThesis, industryContext, growthOpportunities, and FAQ answers.
- OTC Analysis was included and fully populated as per the mandatory requirement for OTC stocks.
- FAQs were tailored to the company's specific business and sector, and the analyst consensus FAQ was omitted due to lack of source data, replaced by a company fundamentals FAQ.